Dianthus Therapeutics, Inc. (DNTH)

NASDAQ: DNTH · Real-Time Price · USD

20.86

+0.96 (4.80%)

At close: Aug 13, 2025, 4:00 PM

20.85

0.00 (-0.02%)

After-hours: Aug 13, 2025, 4:10 PM EDT

Dianthus Therapeutics Employees

Dianthus Therapeutics had 78 employees as of December 31, 2024. The number of employees increased by 25 or 47.17% compared to the previous year.

Employees

78

Change (1Y)

25

Growth (1Y)

47.17%

Revenue / Employee

$62,231

Profits / Employee

-$1,471,205

Market Cap

671.29M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	78	25	47.17%
Dec 31, 2023	53	21	65.63%
Dec 31, 2022	32	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

DNTH News

6 days ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results - GlobeNewsWire
2 months ago - Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference - GlobeNewsWire
2 months ago - Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors - GlobeNewsWire
3 months ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results - GlobeNewsWire
3 months ago - Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September - GlobeNewsWire
3 months ago - Dianthus Therapeutics to Participate in Two Upcoming Investor Events - GlobeNewsWire
5 months ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results - GlobeNewsWire
5 months ago - Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors - GlobeNewsWire